Upsher-Smith Launches Osteoporosis Therapy Fortical In U.S.
This article was originally published in The Pink Sheet Daily
Unigene's nasal calcitonin-salmon product is expected to be sold primarily through managed care as an "economical alternative" to competing agents.
You may also be interested in...
Product approved under 505(b)(2) now faces encroachment through traditional generic pathway.
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications